Printer Friendly Email a Friend PDF

November 15, 2018

The NCCIH Seeks Researchers for an Acupuncture RCT

By Editorial Staff

The National Center for Complementary and Integrative Health (NCCIH) is seeking researchers for a new Funding Opportunity Announcement (FOA)—a Randomized Control Trial (RCT), which will evaluate the impact of, and strategies to best implement acupuncture treatment of older adults (65 years and older) with chronic low back pain (CLBP).1

This announcement comes just months after new director Helene M. Langevin, a supporter of acupuncture, took the reins at NCCIH. This RCT is part of the "Helping to End Addiction Long-term" (HEAL) program, an initiative to speed scientific solutions to the national opioid public health crisis, which reportedly causes 46 deaths a day.2

The FOA requests "investigators with expertise and insights into this area of evidence-based pain management to begin to consider applying. In addition, collaborative investigations combining expertise in acupuncture, pain management, and pragmatic clinical trials will be encouraged, and these investigators should also begin considering applying for this application."

opioids - Copyright – Stock Photo / Register Mark It's important to note that this study will aid in future Medicare coverage: "By addressing gaps in the literature on the benefits and harms of acupuncture in individuals 65=/+, it is anticipated that evidence on improvements in health outcomes derived from this initiative would assist Center for Medicare & Medicaid Services (CMS) in determining Medicare coverage for acupuncture in CLBP."

For more information about this study, or to apply as a researcher please visit grants.nih.gov

References

  1. Notice Number: NOT-AT-19-005. NIH, 2 Nov 2018.
  2. Prescription Opioid Data. Centers for Disease Control and Prevention, 30 Aug 2017.

Acupuncture Today editorial staff members research, investigate and write articles for the publication on an ongoing basis. To contact the Editorial Department or submit an article of your own for consideration, email mailto: .


To report inappropriate ads, click here.